SNG-162 is under clinical development by Shenogen Pharma Group and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase III drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how SNG-162’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SNG-162 overview

SNG-162 (Icaritin) is under development for the treatment of solid tumor, metastatic hepatocellular carcinoma, chronic myelocytic leukemia (CML), b-cell non-Hodgkin lymphoma and androgen sensitive prostate cancer. The drug candidate is administered orally. It is a prenylflavonoid. Icaritin is a ERa36 modulator acts by targeting aryl hyrocarbon receptor (AHR). The drug candidate is developed based on Selective Estrogen Receptor Modulator (SERM) development platform. It was also under development for the treatment of breast cancer.

Shenogen Pharma Group overview

Shenogen Pharma Group Ltd (Shenogen) is a drug discovery and development company that develops therapeutics for cancer treatment. It develops biologic drugs and small molecule targeted at the new estrogen receptor variant. It provides SNG-162 that is a small molecule naturally derived a TCM. Shenogen is also developing second generation small molecule SNG-1153, which is ready for investigational new drug application. Shenogen offers other pipeline products such as SNG-8023 and companion diagnostic kit. The company provides solutions used in treatment of breast cancer, leukemia, prostate cancer and osteoporosis. Shenogen is headquartered in Beijing, China.

For a complete picture of SNG-162’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.